EMA Accepts Rocket (RCKT) Gene Therapy Filing for Fanconi Anemia [Yahoo! Finance]
Rocket Pharmaceuticals, Inc. (RCKT)
Last rocket pharmaceuticals, inc. earnings: 3/5 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
rocketpharma.com
Company Research
Source: Yahoo! Finance
FA is a rare genetic disorder that mainly affects the bone marrow. It is also marked by cancer predisposition and congenital malformations. The MAA acceptance is based on data from a phase I/II study wherein FA patients treated with RP-L102 achieved sustained genetic and comprehensive phenotypic corrections combined with hematologic stabilization. The therapy was well-tolerated in study participants. Rocket also reiterated its plans to submit a similar filing for RP-L102 with the FDA based on the above study. It expects to submit it by first-half 2024. Year to date, Rocket's shares have lost 14.3% compared with the industry's 0.1% fall. Image Source: Zacks Investment Research Currently, the most effective form of treatment for FA is allogeneic hematopoietic stem cell transplant (HSCT). This risky procedure carries multiple side effects and also requires the use of chemotherapy. In the absence of allogeneic HSCT, the primary cause of death is bone marrow failure (BMF), which
Show less
Read more
Impact Snapshot
Event Time:
RCKT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RCKT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RCKT alerts
High impacting Rocket Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RCKT
News
- Should You Retain Your Conviction in Rocket Pharmaceuticals (RCKT)? [Yahoo! Finance]Yahoo! Finance
- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $53.00 price target on the stock.MarketBeat
- Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade) [Seeking Alpha]Seeking Alpha
- Rocket Pharmaceuticals: Multiple Regulatory Submissions Make It A Must Watch [Seeking Alpha]Seeking Alpha
- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "neutral" rating and a $39.00 price target on the stock.MarketBeat
RCKT
Earnings
- 2/26/24 - Beat
RCKT
Sec Filings
- 4/29/24 - Form ARS
- 4/29/24 - Form DEF
- 4/29/24 - Form DEFA14A
- RCKT's page on the SEC website